Evidence map›Paper›PMID 42583146›Full record

ArticleJournal of thoracic disease2026

Clinical characteristics of pulmonary hypertension associated with hereditary hemorrhagic telangiectasia treated with bevacizumab: a single-center case series.

Meng Zhang, Yao Xiao, Wei Guo, Yan Wang, Hui Li, Qing Zhao, Jiancheng Han, Ye Li, Tingting Man, Dongting Liu and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Meng ZhangDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Yao XiaoDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Wei GuoDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Yan WangDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Hui LiDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Qing ZhaoDepartment of Ultrasonography, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Jiancheng HanEchocardiography Medical Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Ye LiEchocardiography Medical Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Tingting ManEchocardiography Medical Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Dongting LiuDepartment of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yongmei WangDepartment of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yong ChenDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Jie LiDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Shengchen DuanDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Wenmei ZhangDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Xiao XueDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Jinjiang LiDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Xiaohui HuDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Wanmu XieDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China Japan Friendship Hospital, Beijing, China.
Shuai ZhangDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China Japan Friendship Hospital, Beijing, China.
Yunxia ZhangDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China Japan Friendship Hospital, Beijing, China.
Zhenguo ZhaiDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China Japan Friendship Hospital, Beijing, China.
Jun WanDepartment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pulmonary hypertension (PH) is a severe complication of hereditary hemorrhagic telangiectasia (HHT). The experience with bevacizumab in HHT-PH is limited. Therefore, the aim was to provide our single-center experience with the use of bevacizumab in patients with HHT-PH. Methods: The clinical data of HHT-PH patients treated with bevacizumab were retrospectively reviewed between September 2021 and June 2024 at Beijing Anzhen Hospital, Capital Medical University. To describe the clinical features of these patients, we recruited pulmonary arterial hypertension (PAH) patients and PH associated with left heart diseases (PH-LHD) patients, matched for age and gender. The symptoms, underlying diseases, medication history, laboratory test results, treatments, and therapeutic responses were investigated retrospectively in all patients. Results: In total, six cases of HHT-PH that were treated with bevacizumab, of which only five received follow-up after completing the 3-month induction therapy. Compared with PAH and PH-LHD patients, HHT-PH patients were characterized by high cardiac index (CI) [HHT-PH Conclusions: Our study found that the hemodynamic profile of HHT-PH patients treated with bevacizumab differed significantly from that of PAH and PH-LHD. There might be patients with a CI below 4 L/min/m

Indexed as

bevacizumabHereditary hemorrhagic telangiectasia (HHT)pulmonary hypertension (PH)

Identifiers

PMID42583146
PMCPMC13460051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.